<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00281567</url>
  </required_header>
  <id_info>
    <org_study_id>205.250</org_study_id>
    <nct_id>NCT00281567</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Comparison of Tiotropium Inhalation Solution (Respimat Inhaler) and Spiriva HandiHaler in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Randomised, Double-blind, Double-dummy, Placebo-controlled, Crossover Efficacy and Safety Comparison of 4-week Treatment Periods of Two Doses [5 μg (2 Actuations of 2.5 μg) and 10 μg (2 Actuations of 5 μg)] of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler, Tiotropium Inhalation Powder Capsule (18μg) Delivered by the HandiHaler in Patients With Chronic Obstructive Pulmonary Disease (COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Comparison of lung function response between tiotropium inhalation solution and Spiriva
      HandiHaler.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2002</start_date>
  <primary_completion_date type="Actual">July 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of trough FEV1 values at the end of 4-week treatment with tiotropium inhalation solution (5 mcg, 10 mcg) to that achieved with tiotropium inhalation powder (Spiriva 18 mcg).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Trough forced vital capacity (FVC) response after 4 weeks (change from baseline)</measure>
    <time_frame>baseline until week 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak response (FEV1 and FVC) to first dose</measure>
    <time_frame>within 3 hours to first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak response (FEV1 and FVC) after 4 weeks</measure>
    <time_frame>within 3 hours after 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-12h and FVC AUC0-12h response after 4 weeks</measure>
    <time_frame>after 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 AUC0-3h and FVC AUC0-3h response after the first dose and after 4 weeks</measure>
    <time_frame>after first dose and after 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Individual FEV1and FVC measurements at each time point</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose morning and evening peak expiratory flow rate (PEFR) measured by patients</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of occasions of rescue therapy used as required (p.r.n. salbutamol)</measure>
    <time_frame>up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time to onset of therapeutic response after first dose</measure>
    <time_frame>after 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with 15% response above baseline for each treatment at each timepoint after first dose</measure>
    <time_frame>at week 4, 12, 20</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with 15% response above baseline for each treatment at each timepoint after 4 weeks</measure>
    <time_frame>at week 8, 16, 24</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">76</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tiotropium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat SMI</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HandiHaler</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD

          -  FEV1 &lt; 60% predicted

          -  FEV1 &lt; 70% of FVC

          -  Smoking history of 10 pack-years

        Exclusion Criteria:

          -  Significant other disease than COPD

          -  Recent history of MI (1 year or less)

          -  Cardiac arrhythmia requiring drug therapy

          -  History of asthma, allergic rhinitis or eosinophil count &gt; 600 mm3

          -  Symptomatic prostatic hypertrophy or bladder neck obstruction

          -  Known narrow-angle glaucoma

          -  Abnormal baseline hematology, blood chemistry or urinalysis

          -  History of cancer within last 5 years

          -  Life-threatening pulmonary obstruction

          -  Cystic fibrosis or bronchiectasis

          -  Tuberculosis

          -  Pulmonary resection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim Study Coordinator</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim KG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Study chairs or principal investigators</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Study chairs or principal investigators</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

